FDA Site Approval: you heard correctly w.r.t. to onsite FDA visit and inspection.
Notes to remember: In 2022 LABS told their shareholders they have "over 20 strong clinical trials" with "many of them in LATE STAGE. But on March 1 of 2023 the update from LABS only included 6 clinical trials in Phase 2 or earlier. Those 6 indicated on March 1 are NOT "late stage". So we have potentially over 14 clinical trials with their "traditional global pharmaceutical partner" that are in late stage and the FDA onsite inspection (Step 11 of Solid's post) is simply then A LEADING INDICATOR PROGRESSING TO COMMERCIALIZATION!
During the Q4 conference call it was emphasized AGAIN that if only 1 of these are approved it will change the 'face of the company'.
A potential leading indicator to add more LABS shares before the buying rush and rising price: Keep an eye out for ANY announcements from Pfizer directly that they have received FDA approval on a new drug containing cannabinoid API's. From there the path is EXTREMELY short to LABS since they are the ONLY ONE in North America fully approved to supply those cannabinoid API's for commercializtion with their pharmaceutical PARTNER....'change the face of the company'. It will be their pharma partner that will make the announcement FIRST because the pharma partner is the point of commercialization relative to the end using consumer.
IF Pfizer announces first of that approval with a time lag to an announcement by LABS, you then have a perfect arbitrage opportunity to start buying more LABS stock before LABS itself issues a press release.
We ARE very close to a major announcement.